AlphAIalphai — Financial news for AI agents
tradingview.comAUG 312 min read$KE

Should You Buy Kimball Electronics Stock After Lackluster Q4 Results?

Kimball Electronics (KE) reported Q4 fiscal 2026 earnings of -$0.01 per share, missing estimates, with revenue down 2.3% YoY. Medical revenues grew 1%, while Automotive and Industrial declined. Despite the weak quarter, management expects fiscal 2027 revenue growth of 7-9%, driven by Medical market expansion and recent acquisitions. KE stock has underperformed peers over the past year.

Original reporting
tradingview.com
Published Aug 31, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 3:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Should You Buy Kimball Electronics Stock After Lackluster Q4 Results? — source image
Source · tradingview.com
Decision brief

The 30-second read

$KENeutralMed
01

Why it matters

The Q4 loss and new guidance provide fresh data for valuation models; cash flow improvement may support future buy‑backs.

02

Market read

Earnings and guidance release for KE offers actionable insight for traders focusing on industrial and medical device equities.

03

What to watch

Potential integration challenges of the Helvoet acquisition and macro‑economic headwinds for automotive demand.

Relevance 7/10Novelty 7/10Timing: post‑earnings release

Background

Kimball Electronics (KE) is a mid‑cap provider of electronic components, recently expanding into medical manufacturing.

Company-level read

Ticker impact

$KENeutralMedium confidence
Context

Kimball Electronics reported Q4 loss of $0.01 per share, missed earnings estimate, and provided FY2027 revenue guidance of $1.535‑$1.56 B.

Expected impact

Potential 5‑10% upside if medical growth accelerates; downside risk if revenue guidance is not met.

Evidence & confidence

Guidance is new and material, but scale is modest and the company remains small‑cap; market reaction may be muted.

Market effects

Sector

Highlights growing importance of medical electronics within the broader industrial sector.

Regional

May boost sentiment for U.S. mid‑cap industrial stocks with medical exposure.

Global

Limited; primarily affects investors focused on U.S. industrial and medical device segments.

Counterpoint

What could challenge this read

The earnings miss and weak automotive exposure could signal deeper demand weakness, warranting a short position.

Key entities

  • company
    Kimball Electronics

    Subject of earnings report and guidance.

  • company
    Helvoet Polymer Technologies

    Recent acquisition expected to add $60 M of revenue in FY2027.

Read at source← All news

Related articles

AUG 20
$KEHighAI 9/10

Kimball Electronics (KE) Q4 2026 Earnings Call Transcript

Kimball Electronics (KE) reported Q4 2026 net sales of $371.6M, down 2% YoY but up 5% sequentially. Fiscal 2026 revenue was $1.431B, with medical segment growth of 11%. Adjusted operating income was $18.1M (4.9% of sales). Guidance for 2027 projects revenue of $1.535B-$1.560B, with medical sales expected to grow significantly due to the Helvoet acquisition.

fool.com3 min
AUG 13
$KEMedAI 8/10

Kimball Electronics Reports Q4 Results, Issues FY2027 Guidance Highlighted by Organic Growth and Helvoet Acquisition · EMSNow

Kimball Electronics (Nasdaq: KE) reported Q4 FY2026 ended June 30, 2026 net sales of $371.6M, up 5% sequentially but down 2% YoY. Operating income was $29.1M (7.8% margin). Diluted EPS was $0.35. Cash from operations was $42.4M; debt fell to $116.6M. FY2027 guidance: net sales $1.535–$1.560B, incl. ~$60M from Helvoet, and adjusted op margin 4.4%–4.7%.

emsnow.com4 min
AUG 12
$KEHighAI 9/10

Kimball Electronics, Inc. (KE): Results of Operations and Financial Condition

Kimball Electronics, Inc. (KE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 KIMBALL ELECTRONICS REPORTS Q4 RESULTS; COMPANY PROVIDES GUIDANCE FOR FISCAL 2027 HIGHLIGHTED BY ORGANIC SALES GROWTH AND ACCRETIVE IMPACT OF THE HELVOET ACQUISITION JASPER, Ind., August 12, 2026 -- (BUSINESS WIRE) -- Kimball Electronics, Inc. (Nasdaq: KE) today anno

SEC EDGAR 8-K6 min
JUL 1
$KEMedAI 8/10

Kimball Electronics (Nasdaq: KE) said it acquired Helvoet Polymer Technologies B.V., a Europe/India medical CDMO

Kimball Electronics (Nasdaq: KE) said it acquired Helvoet Polymer Technologies B.V., a Europe/India medical CDMO for microfluidics, diagnostics, and drug delivery, for €90m (~$103m) excluding adjustments. The deal is ~9x Helvoet 2026E adjusted EBITDA, expected accretive to fiscal 2027 adjusted earnings and to grow Kimball’s medical sales in the low double digits. Helvoet 2025 revenue was ~$56m.

stockhouse.com6 min